Sakeena P. Bairamova

Sakeena P. Bairamova

Auto-generated profile, based on publicly available information

Sakeena P. Bairamova

Serbsky National Medical Research Center of Psychiatry and Narcology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DPDmitry Petelin
Dmitry Petelin
SBS. P. Bairamova
S. P. Bairamova
OSO. Yu. Sorokina
O. Yu. Sorokina
INI. N. Niinoja
I. N. Niinoja
ALA. B. Lokshina
A. B. Lokshina
Beatrice VolelBeatrice Volel
Beatrice Volel
Depression is one of the most common mental disorders in neurological practice. Among other symptoms of depression, a symptom complex represented by apathy, anhedonia, and cognitive impairment plays an important role. This review presents the clinical characteristics of the symptoms described above and discusses modern neurochemical and neuroimaging concepts of their pathogenesis. The problem of pathogenetically substantiated therapy of depression with a predominance of apathy, anhedonia and cognitive impairment is discussed. Fundamental and clinical arguments are presented in favor of the high efficacy of vortioxetine in depression with a predominance of apathy, anhedonia, and cognitive impairment.

31 March 2023 in Research Results in Pharmacology
Verified
Journal Article
Closed access
PDF file
SBSakeena P. Bairamova
Sakeena P. Bairamova
DPDmitry Petelin
Dmitry Petelin
RARoman V. Akhapkin
Roman V. Akhapkin
NKNikita V. Kudryashov
Nikita V. Kudryashov
OSOlga Yu. Sorokina
Olga Yu. Sorokina
Beatrice VolelBeatrice Volel
Beatrice Volel
Introduction: Although neurosteroids have been relatively recently discovered, their significant role in the neurochemical processes and pathogenesis of a number of psychiatric and neurological disorders is now quite clear. First of all, it seems important to clarify the definition of the endogenous neurosteroids as a class of steroids, taking into account the variability of approaches to their description. Currently, neurosteroids include endogenous steroids synthesized in the central nervous system, gonads, or adrenal glands and interacting with GABAA, NMDA, and sigma-1 receptors. Neurosteroid biosynthesis: Biosynthesis of neurosteroids begins with rate-limiting reaction of TSPO binding cholesterol and transporting it into the mitochondria, where pregnenolone is synthesized following the cytochrome P450scc (CYP11A1) impact. Interaction with GABAА, NMDA and sigma-1 receptors: According to the experimental data, neurosteroids act as the most highly potent endogenous allosteric modulators of the GABA receptor; some types of neurosteroids (ALLO, DHEA, etc.) can produce a rapid anxiolytic and anticonvulsant effect. There is some experimental evidence for antipsychotic effects of some neurosteroids realized through NMDA receptors: intracerebral administration of ALLO to laboratory animals can prevent further appearance of motor agitation and other equivalents of psychosis after administration of high doses of amphetamines. It has also been proven in several studies on animal models that neurosteroids exhibit anxiolytic effects through sigma-1 receptors. Conclusion: The article describes the process of neurosteroidogenesis and the effect of neurosteroids on listed receptorsin accordance with already available scientific data. In addition, this paper describes the specific role of various neurosteroids in the development of mental illnesses, including anxiety disorders, depression, and schizophrenia Graphical Abstract

14 February 2024 in Genes
Verified
Journal Article
Open access
PDF file
AMAnna Morozova
Anna Morozova
VUValeriya Ushakova
Valeriya Ushakova
OPOlga Pavlova
Olga Pavlova
SBSakeena Bairamova
Sakeena Bairamova
NANika Andriushchenko
Nika Andriushchenko
KPKonstantin Pavlov
Konstantin Pavlov
The prevalence of mental disorders and how they are diagnosed represent some of the major problems in psychiatry. Modern genetic tools offer the potential to reduce the complications concerning diagnosis. However, the vast genetic diversity in the world population requires a closer investigation of any selected populations. In the current research, four polymorphisms, namely rs6265 in BDNF, rs10835210 in BDNF, rs6313 in HTR2A, and rs1800955 in DRD4, were analyzed in a case–control study of 2393 individuals (1639 patients with mental disorders (F20-F29, F30-F48) and 754 controls) from the European part of Russia using the TaqMan SNP genotyping method. Significant associations between rs6265 BDNF and rs1800955 DRD4 and mental impairments were detected when comparing the general group of patients with mental disorders (without separation into diagnoses) to the control group. Associations of rs6265 in BDNF, rs1800955 in DRD4, and rs6313 in HTR2A with schizophrenia in patients from the schizophrenia group separately compared to the control group were also found. The obtained results can extend the concept of a genetic basis for mental disorders in the Russian population and provide a basis for the future improvement in psychiatric diagnostics.

11 December 2024 in Discover Medicine
Verified
Journal Article
Open access
PDF file
DPDanil Peregud
Danil Peregud
AKAlexey Korolkov
Alexey Korolkov
VBValeria Baronets
Valeria Baronets
KKKirill Kozlov
Kirill Kozlov
ALAnna Lobacheva
Anna Lobacheva
NTNatalia Terebilina
Natalia Terebilina
Peripheral brain-derived neurotrophic factor (BDNF) levels increase during alcohol abstinence in dependent subjects. Meanwhile, the genetic determinants of circulating BDNF this context are poorly understood. Studies of associations between circulating BDNF and single nucleotide polymorphisms (SNPs) of the corresponding gene are mainly restricted by the most studied BDNF SNP rs6265. A recent genome-wide association study demonstrated that the BDNF-related SNP rs75945125 is associated with serum BDNF. However, it is unknown whether this SNP is associated with changes in peripheral BDNF levels in the context of alcohol abstinence. We aimed to assess the association of the BDNF-related SNPs rs75945125 and rs6265 with changes in serum BDNF levels after alcohol withdrawal and the corresponding clinical manifestations. A total of 132 inpatients diagnosed with alcohol withdrawal syndrome were enrolled in the study. Serum BDNF levels were assessed on 2nd, 7th, and 21st days after alcohol withdrawal. Alcohol withdrawal syndrome severity, craving severity, affective symptoms, and cognitive impairment were assessed on 7th and 21st days. BDNF SNPs rs75945125 and rs6265 were genotyped using real-time PCR. BDNF concentrations in the carriers of the rs75945125 C allele on 21st day were higher as compared with TT genotype carriers. BDNF SNP rs75945125 C allele carriers had a longer duration of problem drinking, consumed a lesser volume of alcohol in the last 3 months, and had lower severity of withdrawal syndrome on 7th day compared with TT genotype carriers. BDNF levels were moderated by rs75945125 and rs6265, as well as by the interaction of rs75945125 × rs6265, whereas only the interaction of rs75945125 × rs6265 had an effect on depression scores during abstinence. Thus, the trajectory of serum BDNF changes during alcohol abstinence is determined by both rs75945125 and rs6265. Moreover, BDNF gene-related SNPs are associated with the clinical parameters of alcohol dependence and withdrawal. The longitudinal design without a control group and the relatively small sample size are the limitations of this study. Future studies on the revealed interactions are warranted.

23 November 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SBS.P. Bairamova
S.P. Bairamova
OPOlga Pavlova
Olga Pavlova
SSS.V. Shport
S.V. Shport
OGOlga Gurina
Olga Gurina
KPKonstantin Pavlov
Konstantin Pavlov
Цитохром P450 (CYP450) является ведущим ферментом в биотрансформации большинства психотропных препаратов. Полиморфизмы генов CYP450 определяют эндофенотип пациента относительно активности ферментов семейства и влияют на метаболизм назначаемых антипсихотиков и антидепрессантов. Категоризация пациентов по эндофенотипам в ходе генотипирования, вероятно, поможет упростить подбор терапии в клинической практике. Совместное назначение препаратов, которые могут быть ингибиторами или индукторами изоформ CYP450 в свою очередь может привести к развитию нежелательных реакций или отсутствию эффекта терапии. В статье изложена компиляция известных фармакогенетических рекомендаций относительно четырех основных эндофенотипов метаболизаторов.

21 April 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
DPDmitry Petelin
Dmitry Petelin
SBS.P. Bairamova
S.P. Bairamova
RAR.V. Akhapkin
R.V. Akhapkin
NKN.V. Kudryashov
N.V. Kudryashov
OSO.YU. Sorokina
O.YU. Sorokina
Beatrice VolelBeatrice Volel
Beatrice Volel
Несмотря на доказанную значимость нейростероидов (НС) во многих физиологических процессах, их роль в патогенезе большинства психических заболеваний остается сравнительно малоизученной. В обзоре приводятся клинические данные о влиянии НС на формирование и терапию тревожного расстройства, депрессии, биполярного расстройства и шизофрении. В частности, указывается на неоднозначный характер воздействия НС на ГАМКА- и другие рецепторы. Особый интерес представляет анксиолитический и анксиогенный эффект некоторых НС, антидепрессивный эффект аллопрегнанолона в лечении послеродовой и других форм депрессий, природа кратко-и долгосрочных механизмов антидепрессивных эффектов НС разного вида. Также обсуждается на данный момент пока недоказанная гипотеза о влиянии изменения уровня НС на течение биполярного расстройства, проводится анализ научных данных о развитии шизофренической симптоматики в связи с изменением уровня НС в контексте позитивных и когнитивных симптомов.